Navigation Links
AIT Bioscience Taps Ligand Binding Assay Expert Dr. Ron Bowsher as Senior Research Advisor
Date:9/11/2012

INDIANAPOLIS, Sept. 12, 2012 /PRNewswire/ -- AIT Bioscience is pleased to announce that Dr. Ron Bowsher, an industry expert in bioanalysis of ligand binding assays, has partnered with the company as a senior research advisor bringing with him an impressive background in biotherapeutic drug research in both traditional pharmaceutical and the CRO industries.

"I am excited about my advisory role at AIT Bioscience, because I believe this organization is both highly innovative and customer-focused," said Dr. Bowsher, who has a long and illustrious history in biotherapeutic research and is a pioneer in regulated bioanalysis of macromolecules.

"The AIT Bioscience team is dedicated to providing both innovative and quality services as demonstrated by their cutting-edge use of electronic lab notebooks. I'm looking forward to helping them grow and expand their services for bioanalysis of large molecules, in order to help clients achieve expedited, quality data," he says.  In his role as senior research advisor of ligand binding assays, Dr. Bowsher will advise on technical, regulatory, and business development matters related to ligand binding methods.

"Dr. Bowsher is a pioneer in our industry and we are honored to have him as an advisor to our management team. His demonstrated leadership in ligand binding assays opens our services to a broader pipeline of molecules, allowing more clinical and non-clinical studies to benefit from our fully integrated electronic laboratory documentation system," said AIT Bioscience president Dr. Ron Shoup.

Dr. Bowsher brings more than 35 years experience in the pharmaceutical/biotech and contract research organization industries. He received a bachelor's degree in chemistry from Indiana University and holds a master's degree and doctorate in biochemistry from the Indiana University School of Medicine. He is an adjunct assistant professor of biochemistry and molecular biology at the IU School of Medicine. In addition to his new advisory role at AIT Bioscience, Dr. Bowsher maintains his robust consulting and laboratory businesses at B2S Consulting® (Indianapolis, IN), and B2S Labs (Shelbyville, IN), respectively.  Since 1980 he has published more than 100 research papers and monographs and 105 abstracts. He holds three patents. He is an AAPS Fellow and was awarded an AAPS Presidential Citation for his work on establishing an educational program for ligand binding assays.  In 2012, Dr. Bowsher received the Distinguished Alumnus Award, School of Science, Indiana University-Purdue University (IUPUI), Indianapolis IN.

About AIT Bioscience:

AIT Bioscience, LLC, headquartered in Indianapolis, Ind., is a bioanalytical contract research organization supporting pre-clinical and phase I-III clinical trials. AIT Bioscience provides robust analytical methods, automated sample logistics, with a systems-wide Quality by Design (QbD) operation that support programs through to the investigational new drug and new drug applications. AIT Bioscience has created a new standard for quantitative bioanalytical analysis and drug development in support of small biotech and large pharmaceutical companies. Learn more about AIT Bioscience at www.AITBioscience.com.


'/>"/>
SOURCE AIT Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):